Squarepoint Ops LLC Buys 16,368 Shares of Accuray Incorporated (NASDAQ:ARAY)

Squarepoint Ops LLC raised its stake in Accuray Incorporated (NASDAQ:ARAY) by 36.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,804 shares of the medical equipment provider’s stock after purchasing an additional 16,368 shares during the quarter. Squarepoint Ops LLC owned approximately 0.06% of Accuray worth $122,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ARAY. Ameriprise Financial Inc. acquired a new stake in shares of Accuray in the fourth quarter valued at approximately $35,000. Prudential Financial Inc. bought a new stake in Accuray in the 4th quarter valued at $43,000. ProShare Advisors LLC lifted its holdings in Accuray by 50.7% during the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 9,187 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Accuray during the fourth quarter worth $66,000. Finally, Gabelli Funds LLC increased its holdings in shares of Accuray by 12.5% in the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 5,000 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors.

Accuray Stock Performance

Shares of Accuray stock opened at $1.28 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The company has a market cap of $131.86 million, a PE ratio of -25.60 and a beta of 1.30. The company has a 50 day moving average of $1.53 and a 200-day moving average of $1.87. Accuray Incorporated has a 1-year low of $1.14 and a 1-year high of $2.95.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The firm had revenue of $113.24 million for the quarter, compared to analysts’ expectations of $101.53 million. As a group, equities research analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Accuray from a “hold” rating to a “buy” rating in a research note on Friday, May 30th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.